邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

NLRP3炎症小体与心肌缺血再灌注损伤的研究进展

张熙,  黄兵,  王贵鹏

downloadPDF
文章导航 > 协和医学杂志  > 2022 >  13(2): 296-301
张熙, 黄兵, 王贵鹏. NLRP3炎症小体与心肌缺血再灌注损伤的研究进展[J]. 协和医学杂志, 2022, 13(2): 296-301. doi: 10.12290/xhyxzz.2021-0619
引用本文: 张熙, 黄兵, 王贵鹏. NLRP3炎症小体与心肌缺血再灌注损伤的研究进展[J]. 协和医学杂志, 2022, 13(2): 296-301. doi: 10.12290/xhyxzz.2021-0619
shu
ZHANG Xi, HUANG Bing, WANG Guipeng. Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 296-301. doi: 10.12290/xhyxzz.2021-0619
Citation: ZHANG Xi, HUANG Bing, WANG Guipeng. Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 296-301. doi: 10.12290/xhyxzz.2021-0619
shu

NLRP3炎症小体与心肌缺血再灌注损伤的研究进展

doi: 10.12290/xhyxzz.2021-0619
  • 1.

    新疆医科大学，乌鲁木齐 830000

  • 2.

    武汉大学，武汉 430000

  • 3.

    新疆医科大学第五附属医院心内科，乌鲁木齐 830000

基金项目: 

新疆维吾尔自治区自然科学基金 2021D01C445

详细信息
    通讯作者:

    王贵鹏，E-mail: WFYWGP26@163.com

  • 中图分类号: R542.2+2

Progress of NLRP3 Inflammasome and Myocardial Ischemia Reperfusion Injury

  • 1.

    Xinjiang Medical University, Urumqi 830000, China

  • 2.

    Wuhan University, Wuhan 430000, China

  • 3.

    Department of Cardiology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China

Funds: 

Natural Science Foundation of Xinjiang Uygur Autonomous Region 2021D01C445

More Information

    摘要
  • 摘要: 及时再通阻塞的冠状动脉是降低急性心肌梗死患者死亡率的关键，但实现再灌注的同时可能对缺血的心肌造成二次损伤，即心肌缺血再灌注损伤(myocardial ischemia reperfusion injury, MIRI)。核苷酸结合寡聚化结构域样受体蛋白3(nucleotide binding oligomerization domain-like receptor protein 3, NLRP3)炎症小体通过促进心肌细胞焦亡、级联放大炎症反应和破坏心肌血管内皮细胞，参与了MIRI的整个过程，引起了临床广泛关注。目前，以NLRP3炎症小体及其调节因子为药物靶点的相关研究正在如火如荼地开展，有望为MIRI的预防和治疗提供新的思路。
    Abstract: Timely recanalization of blocked coronary arteries is the key to reduce the mortality of acute myocardial infarction, but reperfusion may cause secondary injury to ischemic myocardium, namely myocardial ischemia reperfusion injury(MIRI). Nucleotide binding oligomerization domain-like receptor protein 3(NLRP3) inflammasome is involved in the whole process of MIRI by promoting cardiomyocyte scortosis, proinflammatory effects of cascade amplification and destruction of myocardial vascular endothelial cells, which has attracted extensive clinical attention. At the same time, related studies on NLRP3 inflammasome and its regulatory factors as drug targets are in full flow, which is expected to provide new ideas for the prevention and treatment of MIRI.
    作者贡献：张熙负责查阅文献、撰写论文；黄兵负责形成论文框架、修订论文；王贵鹏负责对论文进行审校。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文
    • 参考文献(44)
  • [1] 胡盛涛, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34: 209-220. doi:  10.3969/j.issn.1000-3614.2019.03.001

    Hu SS, Gao RL, Liu LS, et al. Summary of The Chinese Cardiovascular Disease Report 2018[J]. Zhongguo Xunhuan Zazhi, 2019, 34: 209-220. doi:  10.3969/j.issn.1000-3614.2019.03.001
    [2] Takahashi J, Yamamoto M, Yasukawa H, et al. Interleukin-22 Directly Activates Myocardial STAT3 (Signal Transducer and Activator of Transcription-3) Signaling Pathway and Prevents Myocardial Ischemia Reperfusion Injury[J]. J Am Heart Assoc, 2020, 9: e014814. doi:  10.1161/JAHA.119.014814
    [3] Wang Z, Zhang SM, Xiao Y, et al. NLRP3 Inflammasome and Inflammatory Diseases[J]. Oxid Med Cell Longev, 2020, 2020: 4063562.
    [4] Zeng C, Wang R, Tan H. Role of pyroptosis incardiovASCular diseases and its therapeutic implications[J]. Int J Biol Sci, 2019, 15: 1345-1357. doi:  10.7150/ijbs.33568
    [5] Yang X, Lin G, Han Z, et al. Structural Biology of nod-Like Receptors[J]. Adv Exp Med Biol, 2019, 1172: 119-141.
    [6] Lu A, Magupalli VG, Ruan J, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflamma-somes[J]. Cell, 2014, 156: 1193-1206. doi:  10.1016/j.cell.2014.02.008
    [7] Zheng DP, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms[J]. Cell Discov, 2020, 6: 36.
    [8] Gong W, Shi Y, Ren J. Research progresses of molecular mechanism of pyroptosis and its related diseases[J]. Immunobiology, 2020, 225: 151884. doi:  10.1016/j.imbio.2019.11.019
    [9] Hooftman A, Angiari S, Hester S, et al. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation[J]. Cell Metab, 2020, 32: 468-478.e7. doi:  10.1016/j.cmet.2020.07.016
    [10] Guo Q, Wu Y, Hou Y, et al. Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis[J]. Front Immunol, 2018, 9: 1197. doi:  10.3389/fimmu.2018.01197
    [11] Yu P, Li YG, Fu WW, et al. Panax quinquefolius L. Saponins Protect Myocardial ischemia Reperfusion No-Reflow Through Inhibiting the Activation of NLRP3 Inflammasome via TLR4/MyD88/Nf-κB Signaling Pathway[J]. Front Pharmacol, 2020, 11: 607813.
    [12] Amin J, Boche D, Rakic S. What do we know about the inflammasome in humans?[J]. Brain Pathol, 2017, 27: 192-204. doi:  10.1111/bpa.12479
    [13] Lei Q, Yi T, Chen C. NF-kappaB-Gasdermin D axis couples oxidative stress and NACHT, LRR and PYD domainscontaining protein 3 inflammasome-mediatedcardio-myocyte pyroptosis following myocardial infarction[J]. Med Sci Monit, 2018, 24: 6044-6052. doi:  10.12659/MSM.908529
    [14] Minutoli L, Puzzolo D, Rinaldi M, et al. ROS-Mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury[J]. Oxid Med Cell Longev, 2016, 2016: 2183026.
    [15] Cinteza M. OK-Flow. Sorry-No-Reflow[J]. Maedica (Bucur), 2019, 14: 323-325.
    [16] Dai YX, Wang S, Chang SF, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-κB/NLRP3 inflammasome signaling pathway[J]. J Mol Cell Cardiol, 2020, 142: 65-79. doi:  10.1016/j.yjmcc.2020.02.007
    [17] Hesse J, Leberling S, Boden E, et al. CD73-derived adenosine and tenASCin-C control cytokine production by epicardium-derived cells formed after myocardial infarction[J]. FASEB J, 2017, 31: 3040-3053. doi:  10.1096/fj.201601307R
    [18] Deng Y, Han X, Yao Z, et al. PPARalpha Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway[J]. Cell Physiol Biochem, 2017, 42: 2255-2266. doi:  10.1159/000479999
    [19] Westerterp M, Fotakis P, Ouimet M, et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogene-sis[J]. Circulation, 2018, 138: 898-912. doi:  10.1161/CIRCULATIONAHA.117.032636
    [20] Sun WJ, Dong SJ, Lu HQ, et al. Beclin-1 overexpression regulates NLRP3 activation by promoting TNFAIP3 in microvASCular injury following myocardial reperfusion[J]. Cell Signal, 2021, 84: 110008. doi:  10.1016/j.cellsig.2021.110008
    [21] Zhou T, Xiang DK, Li SN, et al. MicroRNA-495 Amelio-rates Cardiac Microvascular Endothelial Cell Injury and Inflammatory Reaction by Suppressing the NLRP3 Inflamma-some Signaling Pathway[J]. Cell Physiol Biochem, 2018, 49: 798-815. doi:  10.1159/000493042
    [22] van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction[J]. Eur Heart J, 2017, 38: 828-836.
    [23] Penna C, Aragno M, Cento AS, et al. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades[J]. Oxid Med Cell Longev, 2020, 2020: 9219825.
    [24] Wang L, Peng YF, Song LJ, et al. Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation[J]. Cardiovasc Drugs Ther, 2021. doi:  10.1007/s10557-021-07239-2.
    [25] Opstal TSJ, Fiolet ATL, van Broekhoven A, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome[J]. J Am Coll Cardiol, 2021, 78: 859-866. doi:  10.1016/j.jacc.2021.06.037
    [26] Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383: 1838-1847. doi:  10.1056/NEJMoa2021372
    [27] Schattner A. Colchicine-new horizons for an ancient drug. Review based on the highest hierarchy of evidence[J]. Eur J Intern Med, 2022, 96: 34-41. doi:  10.1016/j.ejim.2021.10.002
    [28] Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses[J]. Semin Arthritis Rheum, 2015, 45: 341-350. doi:  10.1016/j.semarthrit.2015.06.013
    [29] Su XL, Wang SH, Komal S, et al. The caspase-1 inhibitor VX765 upregulates connexin 43 expression and improves cell-cell communication after myocardial infarction via suppressing the IL-1β/p38 MAPK pathway[J]. Acta Pharmacol Sin, 2022. doi:  10.1038/s41401-021-00845-8.
    [30] Yang XM, Downey JM, Cohen MV, et al. The Highly Selective Caspase-1 Inhibitor VX-765 Provides Additive Protec-tion Against Myocardial Infarction in Rat Hearts When Combined With a Platelet Inhibitor[J]. J Cardiovasc Pharmacol Ther, 2017, 22: 574-578. doi:  10.1177/1074248417702890
    [31] Do Carmo H, Arjun S, Petrucci O, et al. The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway[J]. Cardiovasc Drugs Ther, 2018, 32: 165-168. doi:  10.1007/s10557-018-6781-2
    [32] Luo YF, Xiong BJ, Liu HP, et al. Koumine Suppresses IL-1β Secretion and Attenuates Inflammation Associated With Blocking ROS/NF-κB/NLRP3 Axis in Macrophages[J]. Front Pharmacol, 2020, 11: 622074.
    [33] Nazir S, Gadi I, Al-Dabet MM, et al. Cytoprotective activated protein C averts NLRP3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition[J]. Blood, 2017, 130: 2664-2677. doi:  10.1182/blood-2017-05-782102
    [34] Jun JH, Shim JK, Oh JE, et al. Protective Effect of Ethyl Pyruvate against Myocardial Ischemia Reperfusion Injury through Regulations of ROS-Related NLRP3 Inflammasome Activation[J]. Oxid Med Cell Longev, 2019, 2019: 4264580.
    [35] Lu QY, Ma JQ, Duan YY, et al. Carthamin Yellow Protects the Heart Against Ischemia/Reperfusion Injury With Reduced Reactive Oxygen Species Release and Inflammatory Response[J]. J Cardiovasc Pharmacol, 2019, 74: 228-234. doi:  10.1097/FJC.0000000000000710
    [36] Chen A, Chen ZW, Xia Y, et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells[J]. Biochem Biophys Res Commun, 2018, 499: 267-272. doi:  10.1016/j.bbrc.2018.03.142
    [37] Sun Q, Fan J, Billiar TR, et al. Inflammasome and autophagy regulation a two-way street[J]. Mol Med, 2017, 23: 188-195.
    [38] Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation[J]. Immunity, 2013, 39: 311-323. doi:  10.1016/j.immuni.2013.08.001
    [39] Li J, Zhao CT, Zhu Q, et al. Sweroside Protects Against Myocardial ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Pyroptosis Partially via Modulation of the Keap1/Nrf2 Axis[J]. Frontcardiovasc Med, 2021, 8: 650368.
    [40] Guo X, Hu S, Liu JJ, et al. Piperine protects against pyroptosis in myocardial ischaemia/reperfusion injury by regulating the mir-383/RP105/AKT signalling pathway[J]. J Cell Mol Med, 2021, 25: 244-258. doi:  10.1111/jcmm.15953
    [41] Zuo W, Tian R, Chen Q, et al. miR-330-5p inhibits NLRP3 inflammasome mediated myocardial ischaemia-reperfusion injury by targeting TIM3[J]. Cardiovasc Drugs Ther, 2021, 35: 691-705. doi:  10.1007/s10557-020-07104-8
    [42] Jiang S, Cui H, Wu P, et al. Botany, traditional uses, phytochemistry, pharmacology and toxicology of Ilex pubescens Hook et Arn[J]. J Ethnopharmacol, 2019, 245: 112147. doi:  10.1016/j.jep.2019.112147
    [43] Cheng YY, Cheng LK, Gao X, et al. Covalent modification of Keap1 at Cys77 and Cys434 by pubescenoside a sup-presses oxidative stress-induced NLRP3 inflammasome activation in Myocardial ischemia-reperfusion injury[J]. Theranostics, 2021, 11: 861-877. doi:  10.7150/thno.48436
    [44] Xiao Y, Oumarou DB, Wang S, et al. Malva Sylvestris Circular RNA Involved in the Protective Effect of Malva Sylvestris L. on Myocardial ischemic/Re-Perfused Injury[J]. Front Pharmacol, 2020, 11: 520486. doi:  10.3389/fphar.2020.520486
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  594
  • HTML全文浏览量:  82
  • PDF下载量:  60
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-27
  • 录用日期:  2021-09-30
  • 网络出版日期:  2022-01-30
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！